REPOTRECTINIB for ROS1-positive non-small cell lung cancer | Brain metastasis

Inclusion criteria

• {"criterion_text":"- Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.\n- Female or male patients ≥ 18 years of age at the time of signing ICF.\n- Patients must be capable to swallow capsules intact (without chewing, crushing, or opening).\n- Histologically documented NSCLC.\n- Patients may have symptoms attributed to brain metastases.\n- No indication for immediate local therapy (neurosurgery, brain radiotherapy) of brain metastases per local investigator. Note: in case of immediate local therapy is needed, the study’s medical monitor should be consulted\n- Type II leptomeningeal disease per ESMO-EANO guidelines are allowed.\n- Patients with confirmed ROS1 rearrangement. Prior to study enrollment, patients must have had confirmation of ROS1 rearrangement, which should have been determined locally by a certified laboratory using methods such as FISH, NGS, qPCR, or IHC.\n- Measurable disease according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, with at least one measurable brain lesion of ≥10 mm on T1-weighted, gadoliniumenhanced magnetic resonance imaging (MRI).\n- ECOG PS of ≤ 2.\n- Minimum life expectancy of ≥ 6 weeks at screening.\n- No limit in number of prior chemotherapies, immunotherapy or other non-ROS1 TKI regimens.\n- Patients must not have previously received any ROS1 TKI-based treatment.\n- Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan\n- If feasible, archival tumor biopsy sample at baseline (from primary tissue or any metastatic site) should be provided.\n- Patient has adequate bone marrow, liver, and renal function: I. Hematological (without platelet, red blood cell transfusion, and/or granulocyte colonystimulating factor support within 7 days before first study treatment dose): White blood cell (WBC) count > 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100.0 x109/L, and hemoglobin ≥ 8.0 g/dL (≥ 4.96 mmol/L).\n- Patient has adequate bone marrow, liver, and renal function: II. Hepatic: Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (≤ 3 in patients with liver metastases or know history of Gilbert’s disease); alkaline phosphatase (ALP) ≤ 2.5 times ULN; aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times ULN (≤ 5 in patients with liver metastases); international normalized ratio (INR) < 1.5.\n- Patient has adequate bone marrow, liver, and renal function: III. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 40 M L/min/1.73 m2 based on Cockcroft−Gault glomerular filtration rate estimation for patients with creatinine levels above institutional normal.\n- Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as determined by the US National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (v.5.0) (except for alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).\n- Women of childbearing potential (WOCBP) who are sexually active with a non-sterilized male partner must have a negative serum pregnancy test within 14 days before study treatment initiation. In addition, they must agree to use one highly effective method of birth control from the time of screening until 2 months after the last dose of study treatments. Female patients must refrain from egg cell donation and breastfeeding during this same period. Note: Due to a potential loss of effectiveness of hormonal contraceptives caused by interaction with study intervention, if WOCBP use hormonal contraceptives (including oral hormonal contraceptives), they must use either another form of non-hormonal highly effective contraception or a reliable barrier method.\n- Male participants who are sexually active with a WOCBP partner must be surgically sterile or using an acceptable method of contraception from the time of screening until 4 months after the last administration of the study drug. Male participants must not donate or bank sperm during this same period.\n- Patient must be accessible for treatment and follow-up."}

Exclusion criteria

• {"criterion_text":"- Major surgery within four weeks of the start of treatment.\n- History of extensive, disseminated, bilateral, or presence of NCI CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease (ILD) including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, ILD, obliterative bronchiolitis, and pulmonary fibrosis. Patients with a history of prior radiation pneumonitis are not excluded.\n- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise the protocol objectives in the opinion of the Investigator.\n- Presence or history of any other primary malignancy other than NSCLC within 5 years prior to enrollment into the study. Note: Patients with a history of adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma may be included in the study\n- Current use or anticipated need for drugs that are known to be strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or inducers. Note: midazolam requires diligent monitoring in situations where there is an unprecedented necessity for co-administration. These cases should be discussed with the study’s medical monitor.\n- Patients requiring concomitant use of chronic systemic (intravenously [IV] or oral) corticosteroids at doses higher than 8 mg dexamethasone per day or other immunosuppressive medications except for managing adverse events (AEs); (inhaled steroids or intra articular steroid injections are permitted in this study). Note: The use of stable corticosteroid therapy in patients with brain metastases should be discussed with the Sponsor’s Medical Monitor.\n- Type I leptomeningeal disease per ESMO-EANO guidelines.\n- Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.\n- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec).\n- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.\n- Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2.\n- Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity).\n- Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.\n- Peripheral neuropathy grade ≥ 2."}

Primary endpoints

• {"endpoint_text":"- IC-ORR at any timepoint as judged by best central nervous system (CNS) response according to the Response assessment in neuro-oncology brain metastases (RANO-BM) criteria.","definition_or_measurement_approach":"Intracranial objective response rate (IC-ORR) assessed as best CNS response judged centrally using RANO-BM criteria."}

Secondary endpoints

• {"endpoint_text":"- PFS, defined as the period from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1.","definition_or_measurement_approach":"Progression-free survival determined locally by investigator per RECIST v1.1."}
• {"endpoint_text":"- OS, defined as the period from treatment initiation to death from any cause, as determined locally by the investigator.","definition_or_measurement_approach":"Overall survival measured from treatment start to death from any cause."}
• {"endpoint_text":"- EC-ORR, defined as the rate of patients with complete response (CR) or partial response (PR), as determined locally by the investigator using RECIST v.1.1.","definition_or_measurement_approach":"Extracranial objective response rate (CR or PR) per RECIST v1.1 assessed locally."}
• {"endpoint_text":"- CBR, defined as the rate of patients with objective response (CR or PR), or stable disease for at least 24 weeks, as determined locally by the investigator using RECIST v.1.1.","definition_or_measurement_approach":"Clinical benefit rate = CR or PR or stable disease ≥24 weeks per RECIST v1.1 assessed locally."}
• {"endpoint_text":"- DCR, defined as the percentage of patients with advanced cancer whose therapeutic intervention has led to a complete response, partial response, or stable disease.","definition_or_measurement_approach":"Disease control rate = percentage with CR, PR or stable disease."}
• {"endpoint_text":"- TTR, defined as the period from treatment initiation to the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR, as determined locally by the investigator using RECIST v.1.1.","definition_or_measurement_approach":"Time to response measured from treatment initiation to first documented ≥30% tumor shrinkage (CR/PR) per RECIST v1.1."}
• {"endpoint_text":"- DoR, defined as the period from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1.","definition_or_measurement_approach":"Duration of response from first documented objective response to progression or death per RECIST v1.1."}
• {"endpoint_text":"- Best percentage of change in tumor burden (RANOBM) for intracranial lesions 3 and RECIST v.1.1 for extracranial and overall lesions (bicompartmental ORR).","definition_or_measurement_approach":"Best percent change in tumor burden measured intracranially by RANO-BM and extracranially/overall by RECIST v1.1 (bicompartmental assessment)."}
• {"endpoint_text":"- Safety endpoints: Changes from baseline in the EORTC QLQ-C30 and EORTC QLQ-BN20 scales, and symptoms scores.","definition_or_measurement_approach":"Patient-reported QoL changes from baseline using EORTC QLQ-C30 and QLQ-BN20."}
• {"endpoint_text":"- Safety endpoints: Neurological function assessment as per NANO scale.","definition_or_measurement_approach":"Neurological function assessed using the NANO scale."}
• {"endpoint_text":"- Safety endpoints: Safety and tolerability as per NCI-CTCAE v.5.0.","definition_or_measurement_approach":"Adverse events and safety graded per NCI-CTCAE v5.0."}
• {"endpoint_text":"- Exploratory endpoints: Exploratory endpoints can include (but are not limited to): Relationship of treatment efficacy outcomes in all patients with biomarkers analyzed in blood samples.","definition_or_measurement_approach":"Association analyses between treatment outcomes and blood biomarkers (exploratory)."}
• {"endpoint_text":"- Exploratory endpoints Exploratory endpoints can include (but are not limited to): Association of efficacy outcomes in all patients with radiological imaging biomarkers.","definition_or_measurement_approach":"Association analyses between efficacy outcomes and radiological imaging biomarkers (exploratory)."}
• {"endpoint_text":"- Exploratory endpoints Exploratory endpoints can include (but are not limited to): Efficacy endpoints for all patients according to ROS1 gene expression level at baseline.","definition_or_measurement_approach":"Subgroup analyses of efficacy by baseline ROS1 gene expression level (exploratory)."}

Spain

Earliest CTIS Part Ii Submission Date

31-10-2024

Latest Decision Or Authorization Date

09-09-2025

Processing Time Days

313

Number Of Sites

17

Number Of Participants

9

Germany

Earliest CTIS Part Ii Submission Date

14-10-2024

Latest Decision Or Authorization Date

23-09-2025

Processing Time Days

344

Number Of Sites

4

Number Of Participants

4

Austria

Earliest CTIS Part Ii Submission Date

16-10-2024

Latest Decision Or Authorization Date

30-09-2025

Processing Time Days

349

Number Of Sites

2

Number Of Participants

7

Primary sponsor

Full Name

Medica Scientia Innovation Research S.L.

Organisation Type

Pharmaceutical company

Country Of Registered Address

Spain

Contract research organisations

Name

Verum.De GmbH

Responsibilities

CRO

Third parties

• {"country":"Germany","full_name":"Verum.De GmbH","duties_or_roles":"CRO","organisation_type":"Pharmaceutical company"}
• {"country":"Spain","full_name":"Servicio De Asesoria A La Investigacion Y Logistica S.L.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
• {"country":"Spain","full_name":"Lodilat Logistica S.L.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
• {"country":"Spain","full_name":"Oc Vigilance S.L.","duties_or_roles":"Pharmacovigilance","organisation_type":"Pharmaceutical company"}
• {"country":"Spain","full_name":"Eurofins Megalab S.A.","duties_or_roles":"Sample management","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"Spain","full_name":"Hospital Ramón y Cajal","duties_or_roles":"Sample Management","organisation_type":"Health care"}

Co-sponsors

• Medical University Of Vienna